 RAPT Therapeutics Inc NASDAQ:RAPT shares are trading higher by 95 at 36.19 after the company reported topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis. Read more here... RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company. 